Effect of age and plasma concentrations of albumin and alpha 1-acid glycoprotein on protein binding of disopyramide.

PubWeight™: 0.89‹?›

🔗 View Article (PMC 1428016)

Published in Br J Clin Pharmacol on September 01, 1983

Authors

D W Holt, A M Hayler, G F Healey

Articles by these authors

Side effects of long-term amiodarone therapy. Circulation (1983) 3.03

Fatal overdosage with disopyramide. Lancet (1978) 2.96

Smoking and decreased fertilisation rates in vitro. Lancet (1992) 2.92

Purchasing 'legal highs' on the Internet--is there consistency in what you get? QJM (2010) 2.43

Amiodarone pharmacokinetics. Am Heart J (1983) 2.42

Comparison of two strategies for myocardial management during coronary artery operations. Ann Thorac Surg (1994) 2.21

Measuring brain natriuretic peptide. Lancet (1996) 2.03

Evaluation of fetal arrhythmias by echocardiography. Br Heart J (1983) 1.59

Increased plasma endothelin levels in angina patients with rapid coronary artery disease progression. Eur Heart J (2001) 1.54

Simple bioequivalence criteria: are they relevant to critical dose drugs? Experience gained from cyclosporine. Ther Drug Monit (1997) 1.48

TGF-beta quantitation can be tricky. Transplantation (1999) 1.47

A controlled trial of substrate-enhanced, warm reperfusion ("hot shot") versus simple reperfusion. Ann Thorac Surg (2000) 1.38

The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med (2009) 1.36

High-performance liquid chromatographic measurement of amiodarone and its desethyl metabolite: methodology and preliminary observations. Ther Drug Monit (1982) 1.31

Rapid high-performance liquid chromatographic method for the measurement of verapamil and norverapamil in blood plasma or serum. J Chromatogr (1981) 1.26

Paediatric use of mexiletine and disopyramide. Br Med J (1979) 1.23

Amiodarone in testis and semen. Lancet (1985) 1.20

Buying 'legal' recreational drugs does not mean that you are not breaking the law. QJM (2010) 1.19

Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit (2001) 1.17

Death rate from use of ecstasy or heroin. Lancet (2000) 1.12

Amiodarone in pregnancy. Lancet (1983) 1.11

Amiodarone and its desethyl metabolite: tissue distribution and morphologic changes during long-term therapy. Circulation (1985) 1.07

Postmortem assay of digoxin by radioimmunoassay. J Clin Pathol (1975) 1.06

Medical and legal confusion surrounding gamma-hydroxybutyrate (GHB) and its precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4BD). QJM (2008) 1.05

Amiodarone pharmacokinetics. Br J Clin Pract Suppl (1986) 1.02

Rapid high-performance liquid chromatographic method for the measurement of amiodarone in blood plasma or serum at the concentrations attained during therapy. J Chromatogr (1980) 1.02

Therapeutic monitoring of mycophenolic acid. A consensus panel report. Clin Biochem (1998) 1.01

Concentration of circulating plasma endothelin in patients with angina and normal coronary angiograms. Br Heart J (1995) 1.01

High-performance liquid chromatographic measurement of amiodarone and desethylamiodarone in small tissue samples after enzymatic digestion. J Clin Pathol (1983) 1.00

Simple gas-liquid chromatographic method for the measurement of disopyramide in blood-plasma or serum and in urine. J Chromatogr (1978) 1.00

Cardiac troponins and creatine kinase content of striated muscle in common laboratory animals. Clin Chim Acta (2001) 0.99

Accuracy of cyclosporin measurements made in capillary blood samples obtained by skin puncture. Ther Drug Monit (2000) 0.98

Intravenous and oral amiodarone for arrhythmias in children. Br Heart J (1986) 0.98

HPLC assay with ultraviolet detection for therapeutic drug monitoring of sirolimus. Clin Chem (2001) 0.97

Lack of response to intravenous calcium in severe verapamil poisoning. Lancet (1982) 0.97

An immunoassay for the measurement of sirolimus. Clin Ther (2000) 0.96

The United Kingdom Cyclosporin Quality Assessment Scheme. Ther Drug Monit (1986) 0.96

Mexiletine for control of ventricular dysrhythmias in pregnancy. Lancet (1980) 0.96

Identification and measurement of desethylamiodarone in blood plasma specimens from amiodarone-treated patients. J Pharm Pharmacol (1982) 0.95

Peripheral neutrophil inclusions in amiodarone treated patients. Br J Clin Pharmacol (1986) 0.95

The pathogenesis of amiodarone-induced pigmentation and photosensitivity. Br J Dermatol (1984) 0.95

A new method to monitor drugs at dance venues. BMJ (2001) 0.93

Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit (1995) 0.92

Cyclosporine blood concentrations in the management of renal transplant recipients. Transplantation (1986) 0.92

Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure. Kidney Int (2000) 0.91

High-performance liquid chromatographic measurement of atenolol: methodology and clinical applications. Ther Drug Monit (1983) 0.91

Measurement of cyclosporine: methodological problems. Transplant Proc (1986) 0.91

Simple gas-liquid chromatographic method for the measurement of mexiletine and lignocaine in blood-plasma or serum. J Chromatogr (1979) 0.90

Neuropsychological change and S-100 protein release in 130 unselected patients undergoing cardiac surgery. Stroke (1999) 0.89

Serum neopterin in acute coronary syndromes. Lancet (1997) 0.87

Hepatic effects of amiodarone. Br J Clin Pract Suppl (1986) 0.86

Bioavailability of amiodarone. Eur J Clin Pharmacol (1984) 0.86

Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection. J Antimicrob Chemother (2010) 0.86

Gas-liquid chromatographic measurement of lignocaine in small samples of canine myocardium after enzymatic digestion. J Clin Pathol (1979) 0.85

Current opinions on therapeutic drug monitoring of immunosuppressive drugs. Clin Ther (1999) 0.85

Use of troponin-T concentration and kinase isoforms for quantitation of myocardial injury induced by radiofrequency catheter ablation. Eur Heart J (1997) 0.85

Circulating cardiac troponin-T in patients before and after renal transplantation. Clin Chim Acta (2001) 0.84

Therapeutic drug monitoring of cyclosporine. Transplant Proc (2004) 0.84

A limited sampling strategy for the measurement of cyclosporine AUC. Transplant Proc (1990) 0.84

High-performance liquid chromatographic method for the measurement of mexiletine and flecainide in blood plasma or serum. J Chromatogr (1984) 0.84

Blood cyclosporin concentrations and renal allograft dysfunction. Br Med J (Clin Res Ed) (1986) 0.84

Concentration-controlled trials. What does the future hold? Clin Pharmacokinet (1995) 0.84

Therapeutic drug monitoring of immunosuppressant drugs. Br J Clin Pharmacol (1999) 0.83

Creatine kinase MB isoforms: sensitive markers of ischemic myocardial damage. Clin Chem (1994) 0.83

Plasma disopyramide concentrations following a 300-mg oral loading dose in acute myocardial infarction. Ther Drug Monit (1982) 0.83

Mycophenolate mofetil: a report of the consensus panel. Ther Drug Monit (1995) 0.83

Paediatric use of flecainide in supraventricular tachycardia: clinical efficacy and pharmacokinetics. Br Heart J (1989) 0.83

Acute kidney injury reduces the hepatic metabolism of midazolam in critically ill patients. Intensive Care Med (2011) 0.82

High-performance liquid chromatographic measurement of amiodarone and desethylamiodarone in plasma or serum at the concentrations attained following a single 400-mg dose. J Chromatogr (1982) 0.82

Use of amiodarone and digoxin specific Fab antibodies in digoxin overdosage. Br Heart J (1985) 0.82

What evidence is there that the UK should tackle the potential emerging threat of methamphetamine toxicity rather than established recreational drugs such as MDMA ('ecstasy')? QJM (2008) 0.82

Experience with flecainide for the treatment of cardiac arrhythmias in children. Eur Heart J (1988) 0.82

Cardiac consequences and treatment of disopyramide intoxication: experimental evaluation in dogs. Cardiovasc Res (1979) 0.81

The effect of vehicle on the oral absorption of cyclosporin. Br J Clin Pharmacol (1986) 0.81

Use of amiodarone during pregnancy. Postgrad Med J (1985) 0.81

Myocardial injury induced by radiofrequency and low energy ablation: a quantitative study of CK isoforms, CK-MB, and troponin-T concentrations. Pacing Clin Electrophysiol (1998) 0.81

The digoxin-amiodarone interaction. Cardiovasc Drugs Ther (1989) 0.81

Osteoarthritis in temporomandibular joint of Col2a1 mutant mice. Arch Oral Biol (2013) 0.81

Experimental disopyramide poisoning: treatment by cardiovascular support and with charcoal hemoperfusion. J Pharmacol Exp Ther (1979) 0.81

Cardiac troponin T and creatine kinase MB are not increased in exterior oblique muscle of patients with renal failure. Clin Chem (2001) 0.81

Immunosuppressant drugs--the role of therapeutic drug monitoring. Br J Clin Pharmacol (2001) 0.81

Optimizing the use of cyclosporine in renal transplantation. Clin Biochem (1995) 0.80

Elevated serum levels of soluble interleukin-2 receptor, neopterin and beta-2-microglobulin in idiopathic dilated cardiomyopathy: relation to disease severity and autoimmune pathogenesis. Eur J Heart Fail (2001) 0.80

Treatment of disopyramide overdosage. Med J Aust (1979) 0.80

Urinary proteins as a marker of drug-induced renal damage following treatment with cyclosporine or FK 506. Transplant Proc (1991) 0.79

Can vacuum assisted venous drainage be achieved using a roller pump in an emergency? A pilot study using neonatal circuitry. J Extra Corpor Technol (2007) 0.79

Which cyclosporin formulation? Lancet (1996) 0.79

Verapamil and breast-feeding. Eur J Clin Pharmacol (1986) 0.79

Electrophysiological properties of mexiletine assessed with respect to plasma concentrations. Eur J Cardiol (1980) 0.79

Convulsion after disopyramide. Lancet (1978) 0.79

Generic substitution for cyclosporine: what should we be looking for in new formulations? Transplant Proc (1998) 0.78

A survey to determine the blood concentration of cyclosporine 2 hours postdose in stable renal transplant patients. Transplant Proc (2004) 0.78

CYP3A5 genotype had no impact on intrapatient variability of tacrolimus clearance in renal transplant recipients. Ther Drug Monit (2013) 0.78